Volume 3, Number 2 / April issue 2017
Abd Allah A. Abd Elfatah, Mohamed A. Mahmoud, Mohamed A. Saad, Ahmed A. Goma
Role of different CT techniques in grading of liver fibrosis in viral hepatitis patients

This study aims to evaluate the role of perfusion CT in grading of liver fibrosis, seeking for a simple tool that may be helpful in evaluation of a very common problem. Fifty one hepatitis C patients applying for Egyptian ministry of health antiviral therapy (Peginterferon alfa-2b 1.5 mcg/kg weekly + Ribavirin 800 mg daily) were included in the study. All the group were subjected to the routine clinical assessment, lab and imaging protocol. Lab assessment included CBC, AL, AST, liver and kidney function tests, HBsAg, HCV Ab, HCV PCR, abdominal ultrasound, and true cut liver biopsy. Perfusional CT scan was added and perfusional parameters was calculated. These results show that each of portal perfusion, total hepatic perfusion and transit time can be used to differentiate mild from moderate liver fibrosis. The best single factor was portal hepatic perfusion. Using portal hepatic perfusion value of 102 ml /min/100ml showed a sensitivity of and specificity of 83%. At this value efficiency of the test is about 80%.
Keywords: liver fibrosis, CT, HCV, perfusion

Cite this article:
Abd Allah A. Abd Elfatah, Mohamed A. Mahmoud, Mohamed A. Saad, Ahmed A. Goma. Role of different CT techniques in grading of liver fibrosis in viral hepatitis patients. Acta Scientiae et Intellectus, 3(2)2017, 92-120.


  1. Al-Sherbiny M, Osman A, Mohamed N et al. Exposure to Hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg, 2005 Jul; 73(1):44-9.
  2. Annet L, Materne R, Danse E, et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology. 2003; 229: 409–414.
  3. Awaya H, Mitchell DG, Kamishima T, et al. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002;224:769–74.
  4. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 1980; 137(3): 679–686.
  5. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004; 127:S133–43.
  6. Berland LL and Smith JK. Multidetector-array CT: once again, technology creates new opportunities. Radiology 209:327-329, 1998.
  7. Blumgart LH, Hann LE. Surgical and radiological anatomy of the liver and biliary tract. In Blumgart LH, Fong Y [ed]: Surgery of the Liver and Biliary Tract. New York, WB Saunders, 2000, pp 13-14.
  8. Brancatelli G, Federle M P, Ambrosini R, Lagalla R, Carriero A, Midiri M, Vilgrain V. Cirrhosis: CT and MR imaging evaluation. Eur J Radiol. 2007 Jan;61(1):57-69
  9. Brancatelli G, Federle MP, Blachar A, Grazioli L. Hemangioma in the cirrhotic liver: diagnosis and natural history. Radiology 2001; 219:69–74.
  10. Bravo AA, Sheth SG, Chopra S. Review Liver biopsy. N Engl J Med. 2001 Feb 15; 344(7):495-500.
  11. Brink JA, Heiken JP, Balfe DM. Spiral CT: Decreased spatial resolution in vivo due to broadening of section-sensitivity profile. Radiology 185:469-474, 1992.
  12. Brix G, Griebel J, Kiessling F, Wenz F. Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging 2010; 37(Suppl 1):S30–S51.
  13. Cainelli F. Hepatitis C virus and human immunodeficiency virus transmission routes: Differences and similarities. World J Hepatol. May 27, 2013; 5(5): 234–236.
  14. Carlos L, Carneiro J, Hill G. Basic Histology, Text and Atlas. 11th edition. Mc Graw Hill Companies, USA, 2005; Chapter 16. PP: 323-337.
  15. Chen M, Zeng Q, Huo J, et al. Assessment of the hepatic microvascular changes in liver cirrhosis by perfusion computed tomography. World J Gastroenterol. 2009;15:3532–3537.
  16. Chopra S, Dodd 3rd GD, Chintapalli KN, Esola CC, Ghiatas AA. Mesenteric, omental, and retroperitoneal edema in cirrhosis: frequency and spectrum of CT findings. Radiology 1999; 211:737–42.
  17. Clark JM and Diehl AM. "Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis". JAMA 2003; 289 (22): 3000–4.
  18. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis. 2005; 40:951-8.
  19. Cuenod C, Leconte I, Siauve N, et al. Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 2001;218(2):556–561.
  20. Dodd III GD, Baron RL, Oliver III JH, Federle MP. End-stage primary sclerosing cholangitis: CT findings of hepatic morphology in 36 patients. Radiology 1999;211:357–62.
  21. Dodd III GD, Baron RL, Oliver III JH, Federle MP. Spectrum of imaging findings of the liver in end-stage cirrhosis. Part I. Gross morphology and diffuse abnormalities. AJR 1999;173:1031–6.
  22. Doss W, Mohamed M.K, Esmat G, et al. Egyptian national control strategy for Viral Hepatitis 2008-2012. Arab Republic of Egypt, Ministry of Health and Population National Committee for the Control of Viral Hepatitis, April 2008.
  23. Duncan AW, Taylor MH, Hickey RD, et al. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature: 2010, 467(7316); 707-10
  24. El-Zanaty F and Way A. Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health. Cairo: El-Zanaty and Associates and Macro International; 2009. p. 431.
  25. El-Zanaty F and Way A. Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health. Cairo: El-Zanaty and Associates and Macro International; 2009. p. 431.
  26. Fawcett DW. Bloom and Fawcett a textbook of histology. 12th ed. New York: Chapman & Hall, 1994, pp 652 et seq.
  27. Flohr T, Ohnesorge B, Schaller S. Design, technique and future perspective of MSCT. Springer, NewYork. Pp 3-16, 2004
  28. Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000; 355:887–891.
  29. Frevert U, Engelmann S, Zougbédé S, Stange J, et al. Intravital observation of Plasmodium berghei sporozoite infection of the liver. PLoS Biol.: 2005, 3(6); e192
  30. Friederich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960.
  31. Friedman S. Alcoholic liver disease, cirrhosis, and its major sequelae. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa.: Saunders, 2000:804–12.
  32. Gosling JA, Harris PF, Whitmore I, et al. Abdomen: liver. Gosling, Harris, Whitmore and Willan (eds). Human anatomy: color and text, 4th ed. Mosby, Elservier science limited, United Kingdom. 2002; 4: 154-157.
  33. Gray H. Gray's Anatomy, 15th Edition. New York: Barnes & Noble, Books, 1995, 916 et seq.
  34. Guan S, Zhao W, Zhou K, et al. CT perfusion at early stage of hepaic diffuse disease. World J Gastroenterol. 2005 Jun 14; 11(22): 3465–3467.
  35. Gülberg V, Haag K, Rössle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002; 35 (3): 630 – 634.
  36. Hagiwara, M., Rusinek, H., Lee, et al. Advanced Liver Fibrosis: Diagnosis with 3D Whole-Liver Perfusion MR Imaging-Initial Experience. Radiology. 2008; 246(3): 926-934.‏
  37. HarbinWP, Robert NJ, Ferrucci JJ. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980;135:273–83.
  38. Hashimoto K, Murakami T, Dono K, et al. Assessment of the severity of liver disease and fibrotic change: The usefulness of hepatic ct perfusion imaging. Oncology Reports. 2006; 16: 677-683.
  39. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Interntional Journal of STD and AIDS. 2004; 15:7–16.
  40. Heidelbaugh, Joel J, Bruderly M. Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation. Am Fam Physician. 2006 Sep 1; 74(5):756-762.
  41. Hsiao EM, Rybicki FJ, Steigner M. CT coronary angiography: 256-slice and 320-detector row scanners. Curr Cardiol Rep. 2010;12:68–75.
  42. Huo TI, Wu JC, Lin HC et al. Evaluation of the increase in model for end-stage liver disease score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005 Jun; 42(6):826-32.
  43. Iannaccone R, Laghi A, Catalano C, et al. Focal liver lesions in the cirrhotic patient: multislice spiral CT evaluation. Radiol Med 2004;107:304–14.
  44. Ichikawa T, Nakajima H, Nanbu A, et al. Effect of injection rate of contrast material on CT of hepatocellular carcinoma. AJR 2006;186:1413–8.
  45. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983–93.
  46. Itai Y, Hachiya J, Makita K, et al. Transient hepatic attenuation differences on dynamic computed tomography. J Comput Assist Tomogr 1987;11:461–5.
  47. Ito K and Mitchell DG. Imaging diagnosis of liver cirrhosis and chronic hepatitis. Intervirology 2004;47:134–143
  48. Ito K, Mitchell DG, Gabata T, et al. Hepatocellular carcinoma: association with increased iron deposition in the cirrhotic liver at MR imaging. Radiology 1999;212:235–40.
  49. Ito K, Mitchell DG, Gabata T, Hussain SM. Expanded gallbladder fossa: simple MR imaging sign of cirrhosis. Radiology 1999;211:723–6.
  50. Ito K, Mitchell DG, Kim MJ, et al. Right posterior hepatic notch sign: a simple diagnostic MR sign of cirrhosis. J Magn Reson Imag 2003;18:561–6.
  51. Jalan R and Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut. 2000; 46(suppl 3–4):III1–III15.
  52. Kalendar WA. Computed Tomography. Munich; publicis MCD Verlag. 130-131, 2000.
  53. Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 2009;47(1):161-178.
  54. Kanda T, Yoshikawa T, Ohno Y, et al. Perfusion measurement of the whole upper abdomen of patients with and without liver diseases: initial experience with 320-detector row CT. Eur J Radiol. 2012;81: 2470–2475.
  55. Kaplan MM and Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005 Sep 22; 353(12):1261-73.
  56. Khattab MA, Ferenci P, Hadziyannis SJ et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J. Hepatol. 2011; 54:1250–1262.
  57. Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology 2014; 272:322–344
  58. Klingenbeck-Regn K, Schaller S, Flohr T, et al. Subsecond multi-slice computed tomography: basics and applications. Eur J Radiol 31:110-124, 1999.
  59. Koh TS, Thng CH, Lee PS, et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008;249(1):307–320.
  60. Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001; 219: 445–54.
  61. Krinsky GA, Lee VS. MR imaging of cirrhotic nodules. Abdom Imag 2000; 25:471–82.
  62. Kundra V, and Silverman PM. Impact of multislice CT on imaging of acute abdominal disease. Radiol Clin N Am 41; 1083-1093, 2003.
  63. Lafortune M, Matricardi L, Denys A, et al. Segment 4 (the quadrate lobe): a barometer of cirrhotic liver disease at US. Radiology 1998; 206:157–60.
  64. Lauer GM and Walker BD. Hepatitis C Virus Infection. New England Journal of Medicine, 2001; 345:41-52
  65. Lee TY, Ellis RJ, Dunscombe PB, et al. Quantitative computed tomography of the brain with xenon enhancement: a phantom study with the GE9800 scanner. Phys Med Biol 1990;35(7):925–935.
  66. Liu Y, Matsui O. Changes of intratumoral microvessels and blood perfusion during establishment of hepatic metastases in mice. Radiology 2007;243(2):386–395.
  67. Mahadevappa Mahesh. AAPM/RSNA Physics Tutorial for Residents;
  68. Mahesh M. Search for isotropic resolution in CT from conventional through multiple-row detector. Radiographics 22:949-962, 2002.
  69. Majno P, Loubeyre P, Mentha G, et al. Segmental Anatomy of the Liver. In Lencioni R, Cioni D, Bartolozzi C. (eds): Focal Liver Lesions: Detection, Characterization & Ablation. Berlin Heidelberg: Springer-Verlag 2005; Part 2, 53-61.
  70. Mast EE, Hwang LY, Seto DS et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. The Journal of infectious diseases. 2005; 192:1880–9.
  71. Materne R, Smith AM, Peeters F, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med. 2002; 47:135–142.
  72. Materne R, Van Beers BE, Smith AM, et al. Non-invasive quantifi cation of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. Clin Sci (Lond) 2000 ; 99 ( 6 ): 517 – 525.
  73. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998 Nov; 93(11):2022-36.
  74. Meijerink MR, van Waesberghe JH, van der Weide L, et al. Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. Eur Radiol 2008; 18(10): 2345–2354.
  75. Mezban ZD, Wakil AE. Hepatitis C in Egypt. HCV Advocate 2003.
  76. Miles KA, Hayball MP, Dixon AK. Functional images of hepatic perfusion obtained with dynamic CT. Radiology 1993; 188 (2):405 – 411.
  77. Miles KA, Hayball MP, Dixon AK. Functional images of hepatic perfusion obtained with dynamic CT. Radiology1993;188(2):405–411.
  78. Miles KA, Lee TY, Goh V, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 2012;22(7):1430–1441.
  79. Miles KA, Leggett DA, Kelley BB, et al. In vivo assessment of neovascularization of liver metastases using perfusion CT. Br J Radiol 1998; 71 (843):276–281.
  80. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003; 76(Spec No 1):S36–S42.
  81. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999; 30(3):198–205.
  82. Miller FD and Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt, Proceedings of the National Academy of Sciences of the United States of America. Aug 17, 2010; 107(33): 14757–14762.
  83. Mitchell DG, Rubin R, Siegelman ES, et al. Hepatocellular carcinoma within siderotic regenerative nodules: appearance as a nodule within a nodule on MR images. Radiology 1991; 178:101–3.
  84. Mohamoud Y, Mumtaz GR, Riome S et al. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infectious Diseases, 2013 June.
  85. Motosigi U, Ichikawa T, Sou H, et al. Multi-organ perfusion CT in the abdomen using a 320-detector row CT scanner: preliminary result of perfusion changes in the liver; spleen, and pancreas of cirrhotic patients. Eur J Radiol 2012; 81(10):2533–7
  86. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: Suppl 1:2S-10S
  87. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-10
  88. Ng CS, Chandler AG, Wei W, et al. Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. J Comput Assist Tomogr 2012; 36(4): 388–393.
  89. Ohtomo K, Baron RL, Dodd GD, et al. Confluent hepatic fibrosis in advanced cirrhosis: appearance at CT. Radiology 1993; 188:31–5.
  90. Ohtomo K, Baron RL, Dodd III GD, et al. Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 1993; 189:871–4.
  91. Okuda M, Hino K, Korenaga M et al. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999;29:217-222
  92. Onofrio AC, Anandkumar HS, Raul NU. Vascular and Biliary Variants in the Liver: Implications for Liver Surgery. RadioGraphics 2008; 28:359–378.
  93. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: current challenges and future goals. Radiology 2005; 234(3):661–673.
  94. Perry I, Neuberger J. Review Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol. 2005 Jan; 139(1):2-10.
  95. Perz J F, Armstrong G L, Farrington L A, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
  96. Peterson MS, Baron RL, Marsh Jr JW, et al. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000; 217:743–9.
  97. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005; 42(Suppl1): S22–36.
  98. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832
  99. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007 Aug; 82(8):967–75.
  100. Quiroga S, Sebastia C, Pallisa E, et al. Improved diagnosis of hepatic perfusion disorders: value of hepatic arterial phase imaging during helical CT. RadioGraphics 2001; 21:65–81.
  101. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998; 143:2493-2503.
  102. Robin Smithuis. Clinical and anatomical basis for the classification of the structural parts of liver. Medicina (Kaunas) 2006; 42(2) 98-105.
  103. Ronot M, Asselah T, Paradis V, et al. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology 2010; 266(1):135-42
  104. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia, Pa.: Saunders, 2002: 1517–42.
  105. Ryan Stephanie, Mcnicholas Michaele, and Eusttace Stephen. Anatomy for diagnostic imaging. (Elsevier Limited, 2007).
  106. Rydberg J, Buckwalter KA, Caldemeyer KS, et al. Multisection CT: Scanning techniques and clinical applications. Radiographics 20: 1787-1806, 2000.
  107. Sagnelli E, Gaeta GB, Felaco FM et al. Hepatitis C virus infection in households, Infection. 1997 Nov-Dec; 25(6):346-9.
  108. Sahani DV. Perfusion CT: an overview of technique and clinical applications. Accessed May 8, 2012.
  109. Schneider G., Trony B., Bulton C. et al. From Magnetic Resonance Angiography, 2005; p 232. Springer, 2005
  110. Schuppan D, Afdhal N H. Liver cirrhosis. Seminar. Lancet 2008; 371: 838–51
  111. Search for Isotropic Resolution in CT from Conventional through
  112. Seeff LB, Miller RN, Rabkin CS, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132:105-111
  113. Silveira MG and Lindor KD. Primary sclerosing cholangitis, Can J Gastroenterol. Aug 2008; 22(8): 689–698.
  114. Silverman PM, Kalendar WA, and Hazle JD. Common terminology for single and multislice helical CT. AJR; 176: 1135-1136, 2001.
  115. Soliman AM, El hawari SA, Refaey MM et al. Extrahepatic Manifestations of Hepatitis C Virus: An Extending List. Afro-Egypt J Infect Endem Dis 2012; 2(1): 36-53
  116. Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys Med Biol2012; 57(2): R1–R33.
  117. Standring S. The anatomical basis of clinical practice Gray's anatomy text book, 39thed, 2005; PP: 1213: 1225.
  118. Taouli B, Goh JS, LuY, et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 2005; 29:425–9.
  119. Taouli B, Losada M, Holland A, Krinsky G. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 2004; 127: S144–52.
  120. Tchelepi H, Ralls PW, Radin R et al. Review Sonography of diffuse liver disease. J Ultrasound Med. 2002 Sep; 21(9):1023-32.
  121. Thng CH, Koh TS, Collins DJ, Koh DM. Perfusion magnetic resonance imaging of the liver. World J Gastroenterol 2010;16(13):1598–1609.
  122. Thomas DL, Factor SH, Kelen GD et al. Viral hepatitis in health care personnel at the Johns Hopkins Hospital: the seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med 1993;153:1705-1712
  123. Timm, J, Neukamm, M, Kuntzen, et al. Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat 2007, 14, 330–337.
  124. Vandelli C., Renzo F., Romanò L., et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. American Journal of Gastroenterology 2004; 99(5):855-9.
  125. Varenika V, Fu Y, Maher JJ, et al. Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology. 2013 Jan; 266(1): 151-8.
  126. Vilgrain V. Ultrasound of diffuse liver disease and portal hypertension. Eur Radiol 2001; 11:1563–77.
  127. Wang L, Fan J, Ding X, et al. Assessment of liver fibrosis in the early stages with perfusion CT. Int J Clin Exp Med 2015;8(9):15276-15282.
  128. Wedemeyer H, Dore G J and Ward J W. Estimates on HCV disease burden worldwide – filling the gaps. Journal of Viral Hepatitis.2015; 22(Suppl. 1), 1–5
  129. Wolf DC. Cirrhosis, Medscape, 2013 Aug.
  130. Van Beers, Leconte V, Materne R, et al. Hepatic Perfusion Parameters in Chronic Liver Disease Dynamic CT Measurements Correlated with Disease Severity. American Journal of Roentgenology. 2001; 176: 667-673.